Atea Pharmaceuticals, Inc. (AVIR) Stock Price & Analysis
Atea Pharmaceuticals, Inc. (AVIR) closed at USD 4.53 on Thursday, October 15, 2026, down 2.16% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 4.63; the Oct 15, 2026 session ranged USD 4.48–4.78 on volume of 319,365 shares. Market capitalization is $363.33M, with a 52-week range of USD 2.87–6.45 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/AVIR.md
Key facts (AVIR)
- Analysts: Buy (mean 2.33 on a 1–5 scale) (3 analysts), mean target USD 9.42 (range 7–11.25).
- Total return with dividends: 1Y +45.2% vs S&P 500 +18.1%; 5Y -88.5% vs S&P 500 +85.1%.
- Next earnings: 2026-11-11, EPS estimate USD -0.51, revenue estimate $0K.
Analysts (AVIR)
Consensus Buy (mean 2.33 on a 1–5 scale), 3 analysts; mean target USD 9.42 (low 7, high 11.25).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | Morgan Stanley | Target raised | Equal-Weight | $6 → $7 |
Total return (dividends reinvested) (AVIR)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +45.2% | -88.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +45.4% | -35.0% |
| Volatility (annualized) | 51.1% | 73.8% |
| Max drawdown | -33.3% (Mar 2026→May 2026) | -93.1% (Oct 2021→Apr 2025) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 4.53 |
|---|---|
| Change | ▼ 2.16% (down) |
| Previous Close | USD 4.63 |
| Open | USD 4.64 |
| Day Range | USD 4.48 – 4.78 |
| 52-Week Range | USD 2.87 – 6.45 |
| Volume | 319,365 shares |
| Market Cap | $363.33M |
| Exchange | NMS |
Technical Analysis (AVIR)
Nexqual's technical model rates AVIR "SELL" based on 3 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.62 (oversold) |
| vs SMA50 | Below (USD 5.26) |
| MACD | -0.13 (negative) |
Analyst Ratings (AVIR)
Wall Street analysts rate AVIR "Buy" based on 3 analysts, with a mean price target of USD 9.42 (range USD 7–11.25), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 9.42 |
| High Target | USD 11.25 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 2 / 1 / 0 |
Earnings (AVIR)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD -0.51 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.41 vs est -0.56 ▲ beat |
| 2025-12-31 | USD -0.57 vs est -0.49 ▼ miss |
| 2025-09-30 | USD -0.53 vs est -0.42 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (AVIR)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -58.14% |
| Debt / Equity | 0 |
| Current Ratio | 8.13 |
| Total Cash | $219.46M |
| Total Debt | $424,000 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (AVIR)
Nexqual rates Atea Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $219M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$152M (TTM) |
| Efficiency | Critical — ROE -58%, ROA -36.7% |
Ownership (AVIR)
| Insider Ownership | +13.37% |
|---|---|
| Institutional Ownership | +79.19% |
| Shares Outstanding | 80.20M |
| Float | 60.34M |
| Short % of Float | +12.68% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (AVIR)
Atea Pharmaceuticals, Inc. is led by Jean-Pierre Sommadossi (age 69), Founder, Chairman, CEO & President, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Founder, Chairman, CEO & President | Jean-Pierre Sommadossi (age 69) |
|---|---|
| CFO, Executive VP of Legal & Secretary | Andrea J. Corcoran (age 63) |
| Senior Vice President of Investor Relations & Corporate Communications | Jonae R. Barnes |
| Executive Vice President of Chemistry | Adel Moussa |
| Executive Vice President of Early Stage Development | Xiao-Jian Zhou |
Major Backers & Investors (AVIR)
Notable institutional backers of Atea Pharmaceuticals, Inc. include FMR, LLC, BML Capital Management, LLC, Fidelity, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.97% |
| BML Capital Management, LLC | 8.67% |
| Fidelity | 7.3% |
| Tang Capital Management, LLC | 6% |
| Bain Capital Life Sciences Investors, LLC | 2.59% |
| Acadian Asset Management. LLC | 2.54% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 15.31% |
| Vanguard Group | 7.31% |
| Geode Capital | 2.44% |
| State Street | 2.06% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt